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AbstrACt
Objectives Non-randomised clinical trial designs 
involving comparisons against external controls or specific 
standards can be used to support regulatory submissions 
for indications in diseases that are rare, with high unmet 
need, without approved therapies and/or where placebo 
is considered unethical. The objective of this review was 
to summarise the characteristics of non-randomised 
trials submitted to the European Medicines Agency (EMA) 
or Food and Drug Administration (FDA) for indications in 
haematological cancers, haematological non-malignant 
conditions, stem cell transplants or rare metabolic 
diseases.
Methods We conducted systematic searches of 
EMA databases of conditional approvals, exceptional 
circumstances, or orphan drug designations and FDA 
inventories of orphan drug designations, accelerated 
approvals, breakthrough therapy, fast-track and priority 
approvals. Products were included if reviewed by at least 
one agency between 2005 and 2017, the primary evidence 
base was non-randomised trial(s) and the indication was 
for haematological cancers, stem cell transplantation, 
haematological conditions or rare metabolic conditions.
results We identified 43 eligible indication-specific 
products using non-randomised study designs involving 
comparisons with external controls, submitted to the EMA 
(n=34) and/or FDA (n=41). Of the 43 indication-specific 
products, 4 involved matching external controls to the 
population of a non-randomised interventional study 
using individual patient-level data (IPD), 12 referred to 
external controls without IPD and 27 did not explicitly 
reference external controls. The FDA approved 98% of 
submissions, with 56% accelerated approvals; most 
required postapproval confirmatory randomised controlled 
trials (RCT). The EMA approved 79% of submissions, with 
a quarter of approvals conditional on completion of a 
postapproval RCT or additional non-randomised trials.
Conclusions There has been a large increase in 
submissions to the EMA and FDA using non-randomised 
study designs involving comparisons with external controls 
in recent years. This study demonstrated that regulators 
may be willing to approve such submissions, although 
approvals are often conditional on further confirmatory 
evidence from postapproval studies.
bACkgrOund  
Both the US Food and Drug Administration 
(FDA) and the European Medicines Agency 
(EMA) recognise well-designed and executed 
randomised controlled trials (RCT) as the 
gold standard approach in confirming effi-
cacy of a new product.1 However, both agen-
cies acknowledge situations when an RCT 
may be operationally and ethically infeasible. 
Conducting an adequately powered phase 
III RCT in rare diseases can be challenging, 
and the absence of suitable comparators can 
affect RCT feasibility. For example, when 
there is no established standard of care, and 
randomisation to placebo or to no treatment 
could carry a risk of serious or irreversible 
harm, it may be considered medically uneth-
ical to conduct a traditional RCT.2 
Regulators acknowledge these difficulties 
and under some circumstances may be willing 
to accept non-RCT evidence.3 This may be the 
strengths and limitations of this study
 ► Our review was conducted using a systematic 
and transparent approach, and involved in-depth 
extractions and validations of the submission 
summaries.
 ► We were limited to regulators’ summary documents, 
rather than the manufacturers’ original submissions.
 ► The Food and Drug Administration (FDA) does not 
publicly provide information on non-approvals. 
However, we did identify several FDA non-approvals 
by searching for press releases.
 ► We limited our scope to products with prespecified 
designations, with prespecified indications and re-
viewed between 2005 and 2017. Within these, we 
found a high overall approval rate; however, this is 
not intended to generalise to all submissions based 
on non-randomised evidence.
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case when evidence from early non-randomised clinical 
trials (eg, a single-arm phase II trial) suggests that a new 
medicine might offer substantial benefits over currently 
available therapies, particularly where no other licensed 
products are available.3 If approved by regulators, this can 
allow patients access to potentially life-saving medicines 
prior to confirmatory evidence from traditional phase III 
RCTs.
Both the EMA and FDA have approval pathways and 
designations that align with circumstances where the 
evidentiary standards deviate from the typical RCT as an 
adequate and well-controlled investigation of new prod-
ucts.1 The EMA’s exceptional circumstances designation 
applies to products for which comprehensive data cannot 
be provided,4 and its conditional approval mechanism 
enables expedited conditional approval in situations 
when the benefit of immediate availability outweighs the 
risk of less comprehensive data than normally required. In 
the USA, the FDA has a programme similar to the EMA’s 
conditional approval. The FDA’s accelerated approval 
programme enables early approval based on surrogate 
endpoints and is subject to re-evaluation following confir-
matory trials.5 6 The FDA has three other expedited desig-
nations or pathways to address unmet medical need for 
serious conditions: fast-track, breakthrough therapy and 
priority review.7 8 Both regulatory agencies provide a 
designation for orphan drugs.
Recent reviews have focused on products submitted 
through specific FDA and EMA pathways using evidence 
from clinical studies that are not typical RCTs.9–19 Hats-
well et al provided the most recent and comprehensive 
systematic review of products that were submitted to regu-
latory agencies in absence of RCT evidence, irrespective 
of licensing pathway and covering both the FDA and 
EMA regulatory agencies15; however, gaps in knowledge 
remain regarding the design of those non-RCT studies, 
how treatment effect was established when the non-RCT 
evidence was used and how non-RCT designs differed by 
pathway and approval status.
We were interested in updating the review by Hatswell et 
al and learning more about non-randomised trials using 
comparisons with external controls that are submitted 
to the EMA and FDA. Specifically, we aimed to identify 
submissions involving non-randomised clinical trials, 
estimate the proportion of submissions that used explic-
itly defined external controls and characterise external 
control study designs. This systematic review also focuses 
on the regulatory pathways adhered to in these submis-
sions, the designation of products, effect size estimation 
and the relevant conditions of approval (or reasons for 
non-approvals).
MethOds
We wanted to learn more about non-RCT study designs 
with external controls that are used in regulatory submis-
sions. We focused our study on haematological malig-
nancies, conditions related to stem cell transplantation, 
other (non-malignant) haematological conditions and 
rare metabolic diseases (table 1), based on research 
showing that submissions in these therapeutic areas are 
among the most common to involve non-randomised 
evidence.9 12 15 20 We conducted a systematic search of 
EMA and FDA regulatory submissions spanning the years 
2005–2017, focusing on regulatory pathways and designa-
tions that most commonly involve submissions based on 
non-randomised evidence.15 18
In August 2017, we searched the EMA’s database of 
European public assessment reports (EPAR) for human 
medicines with conditional approval, exceptional circum-
stances or orphan medicine designation. We searched all 
products, including those listed as authorised, withdrawn, 
suspended and refused.
We conducted a parallel search of the Drugs@FDA 
database in August 2017, using lists of products licensed 
with the following designations: orphan drug, accelerated 
approvals, breakthrough therapy, fast-track and priority 
approval. The lists available at that time were current to 
December 2016. From this search, we retrieved the rele-
vant Center for Drug Evaluation and Research (CDER) 
summary reviews.
Eligibility criteria (table 1) were applied to each 
identified product with specific indication, based on 
an initial assessment of the summary reviews (EPAR or 
CDER summary review), by two independent reviewers 
(reviewer team: EEK, KM, TJJL). Additional information 
was retrieved from the medical and statistical summaries, 
labels and approval letters if needed. On completion of 
these reviews, we crosschecked the FDA and EMA lists. 
If a product (with specific indication) was identified for 
only one regulatory body, we searched the other’s data-
base to determine its approval status and supporting 
evidence base. The Drugs@FDA database is limited to 
approved products only; therefore, we also searched for 
press releases to determine if the submission was rejected 
by or withdrawn from the FDA.
For each product and each included indication for 
that product, one researcher extracted and a second 
Table 1 Eligibility criteria
Item Criterion for inclusion
Evidence base Primary source(s) of evidence came 
from uncontrolled trial(s), with or without 
an explicit comparison against external 
control(s).
Indication The indication was within one of the 
following broad therapeutic areas:
 ► Stem cell transplants.
 ► Haematological cancers.
 ► Other haematological conditions.
 ► Rare metabolic diseases.
Year Approval by FDA or EMA in or after 2005.
EMA, European Medicines Agency; FDA, Food and Drug 
Administration.
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researcher validated the following data from the EPAR 
(for EMA products) and the CDER summary review, 
medical and statistical summaries (for FDA products) 
(extractors and validators: EEK, KM, SG, TL): product 
name and indication; details of approval status as of 
October 2017; regulatory pathway and designation; and 
study design(s) of primary evidence and comparator 
group submitted as supporting evidence (sample size, 
data source(s), primary endpoint and associated effect 
estimate(s), survival-related effect estimate(s), choice of 
control group(s), methodology used for comparison).
We classed the evidence into three categories based 
on the choice and design of the external controls3: (A) 
used individual patient-level data (IPD) to balance inter-
vention and external control groups (IPD-based external 
controls); (B) explicitly defined the external group 
(descriptions of one or more studies (alone or meta-ana-
lysed) were included in the summary, or citation(s) were 
provided to such studies), but did not attempt to adjust 
for differences between intervention and control groups 
(aggregate-level external controls); and (C) no explicit 
mention of a control group was provided in the summary; 
the comparison appeared to be based on general medical 
knowledge (undefined external controls). In some situ-
ations, it was evident that the manufacturer had not 
provided evidence of type A or B but the regulatory 
review committee sought these data and summarised 
them in their review. These submissions were assigned to 
category C, but annotated to acknowledge that regulatory 
reviewers had identified other types of controls.
The main unit of analysis was an ‘indication-specific 
product’. This counted each drug product, allowing 
products that have two or more different indications to 
be counted for each indication. Data were summarised 
using counts, proportions, means, medians and ranges. 
Analysis was conducted in Microsoft Excel and R V.3.4.1.
Patient and public involvement
This study was a systematic review of regulatory submis-
sion documents and did not involve patients or the public 
in any study phase.
results
Products and supporting evidence
We identified and reviewed submissions for a total of 574 
indication-specific products, representing all submissions 
that received conditional approval, exceptional circum-
stances, or orphan medicine designation from the EMA, 
or orphan drug status, accelerated approval, break-
through therapy, fast-track, or priority approval from the 
FDA. Forty-three indication-specific products submitted 
to either the FDA (n=41) or the EMA (n=34) met our 
inclusion criteria (figure 1), that is, they were approved 
based on non-randomised evidence, reviewed in or after 
2005 by at least one agency and sought approval for an 
indication for a haematological cancer, condition related 
to stem cell transplantation, other (non-malignant) 
haematological condition or rare metabolic disease. 
These 43 indication-specific products consisted of 40 
unique products, three of which were submitted for regu-
latory approval for two indications each.
Within the framework of our inclusion criteria, the 
most common indication-specific products seeking regu-
latory approval were for treatment of haematological 
cancers (figure 2). Twenty-five of the 26 haematological 
Figure 1 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) diagram. EMA, European Medicines 
Agency; FDA, Food and Drug Administration; RCT, randomised controlled trial.
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cancer indication-specific products targeted diseases that 
had relapsed, become refractory to treatment or intol-
erant to treatment (ie, unable to tolerate alternate ther-
apies because of adverse effects); the remaining one was 
an expanded indication for a newly diagnosed biomark-
er-defined paediatric population. Additional details are 
presented in online supplementary table 1.
In total, there were 96 unique studies presented as 
primary or supporting evidence of clinical efficacy for the 
43 indication-specific products. This represented a mean 
of 2.2 studies per indication-specific product (median 2 
studies, range 1–6 studies). Studies were most commonly 
designed as single-arm studies (67%; n=64), typically in 
phase II development (60%; n=58 studies) (figure 3). 
Two studies were designed as RCTs; however, neither 
captured randomised data in the relevant indication. 
One of these studies was in a different indication than 
that being considered for regulatory approval, and the 
other only presented interim data from the intervention 
arm. Half of the studies had a sample size of less than 60 
subjects (p25, p75: 24, 103) (online supplementary table 
2).
The majority of indication-specific products included 
in our review were submitted to EMA and/or FDA in 
the second half of the study period (2012–2017; 71%), 
compared with the first half (2005–2011; 29%). Between 
2005 and 2011, there were, on average, 1.4 submissions 
per year to the EMA and 1.9 submissions per year to the 
FDA. This compares with an average of 4.0 submissions 
per year to the EMA between 2012 and 2017 and 4.3 
submissions per year to the FDA.
Evidence from external control(s) was explicitly 
provided for 16/43 (37%) of the indication-specific 
products: 4 (9%) involved individual-level data collected 
from external controls matched to participants in the 
interventional trials, and 12 (28%) used aggregate-level 
controls. For the remaining 27/43 (63%) indications, 
no supporting studies of outcomes in external control 
groups were described. The four indication-specific 
products with studies presenting individual-level data 
used a variety of methodological approaches (table 2). 
Among the 12 indication-specific products with studies 
Figure 2 Proportions of disease targets of included submissions. ADA-SCID, adenosine deaminase deficiency-severe 
combined immunodeficiency; aHUS, atypical haemolytic uraemic syndrome; ASCT, autologous stem cell transplant; 
HSCT, haematopoietic stem cell transplant; sALCL, systemic anaplastic large cell lymphoma. 
Figure 3 Study design features of included studies (total 
n=96). ‘Other’ study designs included: switchover studies 
(n=1), extensions or subset analyses from previous studies 
(n=3), dose escalation studies (n=4), pilot studies (n=1), 
compassionate use (n=2), retrospective studies (n=2), or 
consensus recommendations and other literature (n=1). N/R, 
not reported; RCT, randomised controlled trial.
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involving aggregate-level external controls, one was 
resubmitted using a matched approach after an initial 
negative recommendation by the Committee for Medic-
inal Products for Human Use (CHMP), and presented 
the analysis as grounds for re-examination. Despite 
the additional data, the CHMP’s recommendation 
remained negative, as the data submitted were still 
considered by the committee to be insufficient to estab-
lish the benefits of the indication. Of the remaining 11 
indication-specific products involving aggregate-level 
external control data, six were based on non-systematic 
literature reviews, one cited one retrospective study and 
four included detailed descriptions of data from specific 
retrospective studies (registry or medical chart review) 
but without further analysis to match the controls with 
the patients in the interventional study (online supple-
mentary table 3).
effect size
Very few relative effect estimates were available. HRs 
comparing overall survival were reported for only 2 of 
the 43 indication-specific products (5%): HRs relative 
to standard of care were: 0.54 (95% CI 0.39 to 0.73) 
for blinatumomab for the treatment of acute lympho-
cytic leukaemia, and 0.39 (95% CI 0.26 to 0.60) for 
pralatrexate for the treatment of peripheral T cell 
lymphoma (table 3).
Objective response rate (ORR) was the most 
commonly reported endpoint in the interventional 
oncology trials. There were 22 estimates of ORR for 
16 indication-specific products; across these 16 indi-
cation-specific product submissions, only one estimate 
was provided for external controls. The single external 
control estimate was presented as a range (ORR=51%–
76%), which was compared against an ORR of 87% for 
the new product based on a non-randomised interven-
tional trial. Across the 16 indication-specific products, 
ORRs in the intervention arms varied considerably, with 
response rates exceeding 90% in some indications yet 
only approximately 25% in others (figure 4). The intra-
indication variability was lower than interindication. For 
example, the ORRs reported to support products with 
indications for relapsed/refractory peripheral T cell 
lymphoma and relapsed/refractory multiple myeloma 
ranged from 23% to 33%. All products were approved 
by at least one agency, which reflects the unmet need 
caused by the exceptionally poor outcomes in absence 
of the new investigational agents.
Additional details are provided in online supplemen-
tary table 4.
Approvals and pathways
Of the 34 submissions to the EMA based on non-ran-
domised evidence, 27 (79%) were approved (figure 5). 
Eight of these approvals (24% of submissions) were 
granted as conditional approvals, of which four were 
conditional on completing an RCT, and four were 
conditional on conducting subsequent non-randomised 
trials because postapproval RCTs were not considered 
feasible or necessary for full marketing authorisation. 
Table 2 Summary of external controls for submissions involving individual patient-level data
Product Source(s)
Year(s) of data 
capture n Key methods
Recombinant 
antithrombin*
Retrospective cohort at US 
and European sites
From 1997 35 Controls selected using eligibility criteria that 
matched clinical trial eligibility criteria.
Modified T cells† European Bone Marrow 
Transplant database
2000–2013 853 Pair-matched analysis, matched on four key 
prognostic factors using a 1:4 matching ratio.
Blinatumomab Six national study groups 
and five large treatment 
centres
>1990 1139 Several different matching approaches were 
applied to three different cohort definitions: 
two propensity score approaches using 
inverse probability of treatment weights 
(IPTW), and a weighted stratified analysis 
using established prognostic factors.
Blinatumomab Systematic literature 
review (24 studies)
NR 2622 Model-based meta-analysis.
Defibrotide sodium Retrospective chart review 
from the same sites as 
uncontrolled interventional 
trial
NR 32 Propensity score stratification. Strict exclusion 
for historical controls and a comparison of 
baseline characteristics.
Defibrotide sodium Center for International 
Bone and Marrow 
Transplant Research
2008–2011 Arm 1=41
Arm 2=55
Observational study involving defibrotide 
sodium (arm 1) and standard of care (arm 2). 
Supporting study.
*Included in the Food and Drug Administration (FDA) submission only.
†Modified with a retroviral vector encoding for a truncated form of the human low-affinity nerve growth factor receptor and the herpes simplex 
I virus thymidine kinase.
NR, not reported.
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Six of the approvals (18% of submissions) were granted 
approval under exceptional circumstances. RCTs for 
these indications were considered infeasible due to the 
rarity of these conditions. In one submission, contra-
vention of medical ethics was also provided as the ratio-
nale for using non-randomised evidence.
The FDA approved 40 of the 41 submissions (98%), 
including all seven indications refused by the EMA. 
Accelerated approvals were granted to 23 (56%) of the 
41 indications reviewed by the FDA (figure 5). Nearly 
90% (n=20) of the accelerated approvals required 
postapproval RCTs to confirm efficacy, suggesting that 
RCTs were deemed feasible yet deferred. For seven of 
these products, however, the confirmatory RCT was 
to be conducted in a first-line population, whereas 
the accelerated approval was for a relapse/refractory 
setting.
There were 14 of 43 (33%) indications that received 
neither accelerated approval from the FDA, nor condi-
tional approval or exceptional circumstances designa-
tion from the EMA. Among these 14, ten were approved 
by at least one agency (seven by the EMA and nine by 
the FDA). Three were expanded indications for haema-
tological cancer products, two were new formulations 
of existing agents, five were biologics for a bleeding 
disorder (n=3) or a rare metabolic disease (n=2) and 
one was for a rare metabolic disease which was granted 
breakthrough and priority review designations by the 
FDA but was not reviewed by the EMA. All 14 products, 
except for one new formulation of an existing product, 
received an orphan designation. Additional data 
are available in online supplementary table 5.
non-approvals and divergent opinions
Few details were available on the single FDA non-approval 
(1/41, 2%), which was one of the four submissions that 
incorporated matched historical control data.
Five indication-specific products (5/34, 15%) were 
refused by the EMA and applications relating to two 
indication-specific products (2/34, 5%) were withdrawn 
(table 4). For six of these seven indication-specific prod-
ucts, the reason for the non-approval/withdrawal was 
attributed to inadequate study design and lack of unbi-
ased evidence from patients receiving comparator treat-
ments. External controls had been explicitly defined but 
not matched to subjects in the interventional trial (n=5), 
or were undefined (n=1). A relative effect estimate was 
available for two indication-specific products; however, 
these effect sizes did not substantially differ from effect 
sizes among approved indications. The seventh indica-
tion could not be authorised, despite having a positive 
risk-benefit profile, because it was similar to another 
orphan product that had market exclusivity (table 4). 
Although all indication-specific product submissions 
providing matched historical control data were approved 
by EMA, two approvals were only granted after re-exam-
ination using new data.
disCussiOn
We systematically reviewed non-randomised trials using 
comparisons with external controls that were submitted 
as the main evidence base in applications for regula-
tory approval for indications in haematological malig-
nancies, conditions related to stem cell transplantation, 
Table 3 Effect size for oncology products reporting overall survival
Intervention and indication Approval status
Intervention Control
Median OS (months)
Intervention 
versus control
Median OS 
(months) Exposure HR
Blinatumomab for ALL FDA, EMA 6.1 Standard of care 3.3 0.536
Clofarabine for ALL FDA, EMA 4.1 No further intervention 2.2 NR
Gemtuzumab ozogamicin for AML FDA only (EMA 
refused)
4.8 NR NR NR
Pralatrexate for PTCL FDA only (EMA 
refused)
14.5 Standard of care 6.1–10* 0.39†
Imatinib for ALL FDA, EMA NR Chemotherapy±HSCT NR NR
Belinostat for PTCL FDA (EMA not 
submitted) 7.9
NR NR NR
Ofatumumab for CLL FDA, EMA 15.4 NR NR NR
Idelalisib for NHL FDA, EMA 20 NR NR NR
*Multiple estimates were provided: 6.1 months and 8.7 months estimated from two different US registries, and 10 months estimated from one 
European Union (EU) registry.
†Multiple estimates were provided. In the initial submission, no estimated HRs were provided; an updated HR was provided by the 
manufacturer based on a matched analysis that was conducted after an initial negative recommendation by the Committee for Medicinal 
Products for Human Use (CHMP); this updated HR estimate was 0.39 (95% CI 0.26 to 0.60).
ALL, acute lymphocytic leukaemia; AML, acute myeloid leukaemia; CLL, chronic lymphocytic leukaemia; EMA, European Medicines Agency; 
FDA, Food and Drug Administration; HSCT, haematopoietic stem cell transplant; NHL, non-Hodgkin’s lymphoma; NR, not reported; OS, 
overall survival; PTCL, peripheral T cell lymphoma.
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other (non-malignant) haematological conditions and 
rare metabolic diseases. These were identified from a list 
of all products with conditional approval, exceptional 
circumstances, or orphan medicine designation from 
the EMA, or orphan drug status, accelerated approval, 
breakthrough therapy, fast-track, or priority approval by 
the FDA. We found that the majority of submissions were 
based on clinical efficacy data from single-arm phase II 
trials, and lacked an explicitly defined group of controls. 
The majority of indications went through an approval 
process for products targeting patients with high unmet 
need (ie, for whom no or only very limited treatment 
options exist, as assessed by the regulatory agency). For an 
additional small fraction of submissions, non-randomised 
evidence was used as RCTs were deemed infeasible, most 
often due to the rarity of the disease.
When comparing the time periods from 2005 to 2011 
with that from 2012 to 2017, we found a noticeable increase 
in the number of submissions of interest. A similar obser-
vation was made by Beaver et al5 in their review of acceler-
ated approvals for indications in malignant haematology 
and oncology drugs by the FDA. The authors also noted 
that the majority of accelerated approvals (72%) were 
based on evidence from single-arm trials. The number 
of approval processes based on non-RCT evidence is 
thus increasing also in the broader context of oncology 
indications. However, even though the use of non-RCT 
studies may bring treatments to patients earlier, it can 
lead to difficulties for physicians and payers when they 
assess the evidence. DeLoughery and Prasad6 highlighted 
a number of consequences to the increase in the approval 
of therapies based on single-arm, uncontrolled data, 
specifically in oncology, where surrogate markers, such as 
response rate, are increasingly being used (according to 
their review). They argue that it is difficult for physicians 
and payers to gauge the efficacy of an approved therapy 
Figure 4 Objective response rate in haematological oncology products, by indication. Colour coding reflects approval status: 
dark green=approved by both agencies; light green=approved by Food and Drug Administration (FDA) only; ‘−2’ indicates more 
than one estimate was available (second estimate). CLL, chronic lymphocytic leukaemia; CTCL, cutaneous T cell lymphoma; 
MCL, mantle cell lymphoma; MM, multiple myeloma; NHL, non-Hodgkin’s lymphoma; ORR, objective response rate; PTCL, 
peripheral T cell lymphoma; sALCL, systemic anaplastic large cell lymphoma; WM, Waldenström macroglobulinaemia. Note:  
Lenalidomide and pomalidomide were approved by European Medicines Agency (EMA) using randomised controlled trial (RCT) 
evidence.
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based on limited non-randomised evidence, no compar-
isons to pre-existing therapies and a finding that when 
larger studies are undertaken, the efficacy can oftentimes 
appear reduced.
We did not identify any specific characteristics that 
were clearly associated with approval status, and deci-
sions reached by the FDA and EMA were often divergent. 
These findings illustrate the individualised multifactor 
decision-making process for regulatory submissions. 
In non-randomised studies, the questions required to 
address any gaps in available evidence are variable and 
difficult to quantify; thus, it must be left to the expert 
judgement of the review committees who may also request 
that special advisory groups (SAG) determine which 
questions need to be addressed. Documentation issued 
by the EMA and FDA stops short of providing explicit 
Figure 5 Summary of approval status, and regulatory pathways and designations. Left: EMA submissions (n=34). Right: FDA 
submissions (n=41). EMA, European Medicines Agency; FDA, Food and Drug Administration. 
Table 4 Rationale for EMA non-approvals
Product Reason for non-approval/withdrawal Divergent positions
Refused
Pralatrexate for PTCL Concerns about the external validity due to the 
non-randomised study design. Historical data not 
considered to be acceptable, even when matching 
algorithm applied to support grounds for re-
examination.
The product should have been 
considered for conditional approval.
Romidepsin for PTCL Lack of comparator group in trial made evaluation of 
clinical benefit impossible.
The product should have been 
considered for conditional approval.
Gemtuzumab ozogamicin 
for AML
RCT was considered feasible in this population and did 
not accept the grounds for which non-randomised data 
were provided.
NR
Human heterologous 
liver cells for urea cycle 
disorders
Concerns regarding the risk of bias in the clinical 
trial (specifically: selection bias) and in the historical 
controls. The effect size was not considered convincing 
enough, even for a conditional approval.
The benefit/risk balance was seen 
as positive for an approval under 
exceptional circumstances.
Taliglucerase alfa for type 1 
Gaucher disease
Similarity with existing marketed agent. NR
Withdrawn
Omacetaxine 
mepesuccinate for CML
Use of single-arm trials did not demonstrate ‘dramatic 
activity’, and historical data were not considered 
reliable.
NR
Vorinostat for CTCL Safety and efficacy could not be adequately assessed 
due to the lack of comparator group.
NR
AML, acute myeloid leukaemia; CML, chronic myeloid leukaemia; CTCL, cutaneous T cell lymphoma; EMA, European Medicines Agency; 
NR, not reported; PTCL, peripheral T cell lymphoma; RCT, randomised controlled trial.
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guidance on the use of non-randomised evidence. EMA 
guidance on clinical trials in small populations states 
that the use of lower quality evidence (vs small amounts 
of high-quality evidence) will be evaluated on a case-
by-case basis.21 FDA guidance for industry states that 
historically controlled data would be persuasive if there 
was a ‘large difference’ between new data and historical 
experience, without specifying the desired magnitude 
of effect.7 While some researchers have detected a statis-
tical difference in the distribution of effect sizes between 
EMA approvals that require further testing in RCTs versus 
approvals requiring no further testing, no clear threshold 
has been detected. To our knowledge, no empirical data 
have been used to compare effect sizes between approvals 
and non-approvals.13
Both the FDA and EMA provide individual guidance to 
manufacturers throughout drug development. Enhanced 
communication is available for products with specific 
designation/pathways, such as the FDA’s fast-track and 
breakthrough designations and EMA’s Priority Medicines 
(PRIME) programme.7 22 Other adaptive pathways in 
Europe extend early discussions to include patient advo-
cacy groups and health technology assessment bodies.23 
In previous research that evaluated EMA approvals of 
oncology products through conditional approval versus 
full marketing authorisation, products receiving condi-
tional approval had more frequent referrals to SAGs, 
providing expert recommendation on scientific and 
technical matters.14 In our review, we similarly saw several 
examples where the inclusion of historical control data 
was based on regulators’ recommendations either prior 
to or during the review process.
There were few submissions involving individual-level 
data (4 indications (9%) (3 (9%) EMA submissions; 3 
(7%) FDA submissions)). The use of matching, stratifica-
tion or reweighting in the three most recent submissions 
involving IPD is consistent with literature on observa-
tional study design24 25 and with recent guidance on using 
IPD to estimate treatment effect in observational studies.26 
In the absence of head-to-head evidence, and given that 
new interventions are typically limited to investigational 
settings, this form of adjusted comparison with external 
control groups represents the best approach to producing 
an unbiased estimate of relative effect; however, they were 
surprisingly uncommon. This may be due to the fact that 
an optimal study design may not always be possible, as 
data availability for external controls can be limited, so 
that the study design must be chosen within the options 
available.
Two-thirds (n=27 out of 41) of FDA submissions and 
just over half of EMA submissions included in this study 
(n=18 out of 34) would appear to involve undefined 
external controls, and 100% of these FDA submissions 
and 95% of these EMA submissions were approved. 
Among our three predefined types of external controls, 
these represent the lowest quality of evidence carrying 
the greatest risk of bias in estimating effect size. Although 
the external controls were not described in the regulatory 
bodies’ summary reports of the evidence presented by 
manufacturers, it is possible that further clinical context 
was provided in the actual manufacturers’ submissions, 
or requested by the agencies but not described in the 
summary report: For example, the values used as null and 
alternative hypotheses in the clinical trial study design. 
Furthermore, we observed some cases when manufac-
turers did not provide external control data but the 
regulators themselves conducted a review of expected 
outcomes among external controls. Thus, decisions were 
made in reference to the clinical context current at the 
time of decision-making, but that context was not always 
made explicit in the summary documents.
Our review findings corroborated a previously iden-
tified trend towards a relatively higher likelihood of 
approval by the FDA relative to the EMA.15 Using semi-
structured interviews with regulators, Tafuri et al27 
revealed that both agencies are aware that they make 
different decisions based on the same data. In the inter-
views, regulators attributed this to several factors: (1) a 
greater willingness by the FDA to approve drugs based on 
phase II single-arm trials and based on promising effects 
rather than demonstrated clinical benefit; (2) the FDA’s 
ability to independently review trials’ raw data files versus 
EMA’s reliance on FDA’s findings; (3) an assumption of 
cultural differences with US regulators more willing to 
guarantee quick access to new anticancer treatments; and 
(4) the organisational structure of the review committees 
such that the USA review is done by committees special-
ised into specific therapeutic areas, whereas the Euro-
pean Union system is based on committee members who 
do not necessarily hold the specific expertise (although 
they do consult with medical experts).
Our review was conducted using a systematic and trans-
parent approach, and involved in-depth extractions and 
validations of the submission summaries. Despite this, 
our study was subject to several limitations. First, we were 
limited to regulators’ summary documents, rather than 
the manufacturers’ original submissions. As a result, some 
details on external control groups may have been omitted, 
and information relating to communication between 
regulators and manufacturers was sparse. Knowledge 
of the ongoing communication between manufacturer 
and regulatory agencies would help contextualise the 
decision to submit based on non-randomised evidence. 
Second, the FDA does not publicly provide information 
on non-approvals. However, we did identify several of 
these FDA non-approvals by searching for press releases 
for all EMA submissions that were not in the FDA data-
base; although we may have missed some submissions that 
were refused by the FDA and not submitted to the EMA. 
Third, our search, while systematic in nature, was not an 
exhaustive search of all submissions to FDA and EMA. We 
limited our scope to products with prespecified designa-
tions, with prespecified indications and reviewed between 
2005 and 2017 by at least one agency. In cross-referencing 
our list of included products with those identified by 
Hatswell et al, who reviewed every single submission to the 
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EMA and FDA, we were confident that our strategy yielded 
a reasonably comprehensive set of products within the 
prespecified indications of interest and the time frame 
of our review. Furthermore, we did not conduct a formal 
inter-reviewer reliability assessment during the study 
selection process, and we are therefore not able to quan-
tify the level of agreement of the two reviewers on the 
inclusion or exclusion of the reviewed submissions in this 
study. Finally, by limiting our search to select designations 
and a subset of indications of interest, we found a high 
overall approval rate (98% of submissions were approved 
by one or both agencies); however, this is not intended to 
generalise to all submissions based on non-randomised 
evidence. Our evidence base was limited to a selected 
set of indications, and submissions were identified based 
on the product having been granted one of several 
designations that are more likely to be associated with 
non-randomised evidence. Furthermore, our search was 
not designed to identify situations where manufacturers 
considered seeking approval based on non-randomised 
evidence but instead elected to conduct an RCT, based on 
initial discussions with regulators.
This current review builds on what is currently known 
regarding the use of uncontrolled trials in regulatory 
submissions, and accelerated pathways for approval. We 
have brought other research more up-to-date, and we 
characterised the use of external control groups, which 
had not been addressed previously. Several researchers 
previously focused on features of EMA submissions 
for orphan medicines (2000–2013),19 and medicines 
receiving conditional approval or accelerated assessment 
(2006–2016).16 17 Others have researched FDA approvals 
of oncology orphan drugs (up to 2010),18 20 oncology 
drugs approved without an RCT (1973–2006),9 drugs 
granted accelerated approval (1992–2017; 2009–2013)10 
and characteristics of postapproval studies approved with 
limited evidence (2005–2012).11 Hatswell et al15 included 
both FDA and EMA decisions in their review of products 
submitted without RCT evidence, with the primary objec-
tive being to enumerate and compare approvals by these 
two regulatory bodies. Though not a specific objective of 
their study, these studies discussed the lack of apparent 
threshold regarding what constituted a sufficiently large 
effect size to merit approval in absence of an RCT, which 
is consistent with our findings that encompassed an addi-
tional 17 new indications approved after the end of their 
study period.
COnClusiOn
There has been a large increase in submissions to EMA 
and FDA used non-randomised study designs involving 
comparisons with external controls in recent years, with 
most submissions approved in the diseases we reviewed, 
often conditional to further confirmatory evidence from 
postapproval studies. Based on this selection of 43 indi-
cations that had pathways/designations relating to expe-
dited review or orphan drug status, it is evident that 
when a product’s benefit outweighs the limitations of the 
evidence, regulators may accept evidence from uncon-
trolled trials, with or without explicit comparisons to 
external controls, as the primary evidence base for regula-
tory approval. The approvals are usually provisional, such 
that a commitment by the submitting entity to provide 
further evidence is required. With the rise of personalised 
medicine, which can address urgent unmet need, yet is 
associated with smaller biomarker-defined target popula-
tions, this trend of relying on non-randomised evidence 
in initial regulatory review may continue to grow.
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